COVID-19 clinical outcomes in type-2 diabetic patients on DPP4-inhibitors

Keywords: COVID-19 infection, ICU admission, mortality, severity, type 2 diabetes


It has been suggested that dipeptidyl peptidase 4 (DPP4) overexpression is associated with COVID-19 severity. We aimed to evaluate the clinical outcomes in people with COVID-19 infections and type 2 diabetes (T2DM) treated with DPP4 inhibitors in order to explore the impact of treatment with DPP4 inhibitors on adverse in-hospital outcomes. This retrospective multi-center study included 400 hospitalized people with T2DM and confirmed COVID-19 infection. The composite outcomes, including ICU admission, invasive ventilation and in-hospital mortality, were compared between patients who received DPP4 inhibitors before admission and those treated by other glucose-lowering drugs (GLDs), applying regression models. A total of 54 (13.5%) patients were treated with DPP4 inhibitors. Considering the potential confounders, the odds of the composite outcome of intensive care unit (ICU) admission, invasive ventilation, and death were significantly lower in patients treated with DPP4 inhibitors compared to their counterpart group (OR: 2.52, (1.05–6.01), P=0.04). Previous treatment with DPP4 inhibitors lowers the risk of adverse in-hospital outcomes in people with T2DM and COVID-19 infection.

How to Cite
Najmaldin, Atousa, Pardis Sadeghipour, Hoda Aryan, Homa Abri, Nahid Hashemi-Madani, Nadaer Tavakoli, and Mohammad Ebrahim Khamseh. 2024. “COVID-19 Clinical Outcomes in Type-2 Diabetic Patients on DPP4-Inhibitors”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 31 (2), 165-69.